Company intelligence / Profile preview

Corvus Pharmaceuticals

Burlingame, California, United Statescorvuspharma.com ↗

Ownership: Public · CRVS
Development stage: Phase 3

Overview

Soquelitinib has shown safety and efficacy signals in early cohorts of atopic dermatitis patients using rigorous endpoints; interim data from refractory T-cell lymphoma showed tumor responses; ciforadenant demonstrated activity alone or combined with atezolizumab in advanced renal cell cancer

Therapeutic areas: OncologyImmunologyDermatology
Modalities: Small molecule inhibitorsMonoclonal antibodies
Industry: Biotech

Drug pipeline

5 assets

soquelitinib

4 more assets in the full pipeline.

Request access →

Partnerships

Angel PharmaceuticalsKidney Cancer Research Consortium

Financials

Market cap: $1.1B
Total revenue: $0
Enterprise value: $906.4M

Beyond the preview

Go deeper on Corvus Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Corvus Pharmaceuticals.

Explore the full profile